Elmar Nurmemmedov, PhD, MBA

ASSISTANT PROFESSOR

Elmar Nurmemmedov, PhD, MBA, is an Assistant Professor at The Scintillon Research Institute. Dr Nurmemmedov has dedicated much of his scientific career to drug discovery in the field of ‘challenging’ drug targets, particularly transcription factors. At Scintillon Institute, Elmar’s research is focused on preclinical pharmacology of novel therapeutics with particular focus on:

- Mechanism of action and acquired resistance of novel therapeutic modalities (small molecules, Protacs, peptides);
- Method development for efficient drug discovery, such as biophysical and cellular methods;
- Challenging drug targets and novel methodologies for targeting;
- Utilization of chem-informatics, bio-informatics and genomics tools for interrogation of novel drug targets and therapeutic candidates.

Elmar has received his PhD degree from Lund University, Sweden, in molecular biophysics. During his postdoctoral training at Harvard Medical School, he contributed to drug discovery studies for sickle cell anemia. Subsequently during his postdoctoral training at Scripps Research Institute, Elmar successfully led the drug discovery effort for beta-catenin, a key regulator of colon cancer. Some of these studies led to preclinical drug development programs. Most recently, at Saint John’s Cancer Institute, Dr Nurmemmedov led the WNT research program with a focus on its therapeutic utility of novel therapeutics and combination therapies.